Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Verisante Technology Inc. V.VRS


Primary Symbol: V.VER.H

Verisante Technology Inc is a Canada based medical device company. It is engaged in commercializing medical systems for the early detection of cancer. The products of the company are Verisante Aura which is for skin cancer detection and Verisante Core which is for lung, colon and cervical cancer detection. It utilizes a cancer detection platform while the operating software and probe technology. The group generates revenue from the sale and renting of its medical devices.


TSXV:VER.H - Post by User

Bullboard Posts
Comment by electricsocketson Mar 01, 2013 11:18am
343 Views
Post# 21062159

RE: FDA approval

RE: FDA approval

my guess is FDA approval will be very late 2014 or early 2015 - this will likely be a full PMA application with required US clinical trials as a class III device - anything less would be a pleasant and unexpected surprise. I expect that once the company announces the confirmed FDA process with timelines the market should start taking notice and valuing accordingly. 

IMO - comparing melafind to verisante aura for FDA approval process is apples to oranges for the most part - as the devices are entirely different as are the uses. Very generally they are both to assist in the identification of melanoma - but that is a very broad based analysis when looking at the background science of each device. 

I wrote about my opinion on the Melafind FDA process in an earlier seekingalpha blog post - interesting bits as follows: 

 

(Melafind)Statistical method used to calculate the device sensitivity at 98% was chosen by Mela Sciences as a one-sided exact Mid-p binomial method. Some view this as a weaker statistical evaluation. The FDA certainly voiced this concern despite approving. Comparing this method to the Clopper-Pearson, Score methods and the two-sided Mid-p method the FDA showed much lower results.

Please see: www.fda.gov/downloads/AdvisoryCommittees...

and

www.fda.gov/downloads/AdvisoryCommittees...

Most importantly in my mind, is the issue of Melafind Non-Evaluables- these were not included in the assessment of melafind's accuracy but should be taken into consideration. Let's put this into perspective: in Melafind's clinical study, of the 1831 enrolled lesions, 162 were deemed to be non-evaluable, meaning scanned with no result given, of which included 27 pathology confirmed melanomas. Once hair is shaved, alcohol applied and suspicious lession scanned using the Melafind device, approximately 9% of all these scanned lesions were non-evaluable by the device and of those lesions, 16.7% were confirmed melanomas.

*****

Again just my thoughts & personal opinions, nothing more. Those FDA links about melafind are good reads - better than any NR link on the company website.....

good luck & do your own DD. 

Bullboard Posts